Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Valneva SE
Public Company Edition: Mergers with special purpose acquisition corporations may be heating up, but in addition to the Surrozen and Tango SPAC deals Recursion and Biomea launched initial public offerings. Also, Organon sells $5.6bn worth of notes to fund spinout from Merck & Co.
Coronavirus Notebook: EMA Probes Janssen Vaccine Blood Clot Reports, UK Advises 12-Week Dosing Gap For Moderna
The AZ vaccine is now under EU scrutiny over capillary leak syndrome, while Valneva has reported positive results with its product. The global COVAX initiative has delivered more than 38 million doses of vaccines to over a hundred countries.
With $845m raised to date, ElevateBio will keep building its cell and gene therapy manufacturing capabilities and continue creating new companies and partnerships, but with a global focus.
Two US VCs have led a large $75m series B financing of Belgium’s AgomAb Therapeutics, which is gaining traction in developing antibodies that act on the HGF-MET pathway, potentially reversing fibrosis and allowing damaged tissues to regain function.
- Contract Research, Toxicology Testing-CRO
- Drug Delivery
- Drug Discovery Tools
- Synthesis Technologies, Production Processes
- Other Names / Subsidiaries
- BliNK Biomedical SAS
- Crucell Sweden AB
- Iomai Corporation
- Intercell USA, Inc.
- Intercell AG, Vivalis